Table 4 Clinical studies of MGCD0103

I

Advanced solid tumor(38)

Three times per week for 2 of every three weeks

45 mg/m²/d

[113]

I

Relapsed or refractory AML (22), MDS (5), ALL(1) and CML (1)

Three times weekly without interruption

60 mg/m²/d

[114]

I/

Gemcitabine

Solid tumor(24/I and 4/II)

Three times weekly for MGCD0103 and weeklyX3 for Gemcitabine in 28-days cycle

90 mg/d and PR: 40% in 2 out of 5 pancreatic carcinoma.

[115]

II

Relapsed or refractory NHL(33 of DLBCL and 17 of FL)

Three times weekly without interruption

Started 110 mg, then decreased to 85 mg. RR for DLBCL 23.5% and PR for FL 10%.

[116]

II

Relapsed or refractory HL(33)

Three times weekly in 28 days cycle

85 mg or 110 mg.

OR 38%.

[117]